In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...

Valued at a market cap of $9.6 billion, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

RNA vaccines train the immune system in a similar way to traditional vaccines, but they use a different strategy to get there ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

As the 2020 pandemic became a distant memory and millions of Americans returned back to their old lives, some were left ...

US mRNA specialist Moderna (Nasdaq: MRNA) has announced that its manufacturing facility in the UK has been granted a manufacturer’s license by the Medicines and Healthcare products Regulatory Agency ...

The surprise delay is casting new uncertainty on the fate of another vaccine awaiting FDA action: Moderna’s next-generation Covid-19 shot, called mRNA-1283, which is set for a decision by May 31.

Vaccine stocks are down after the health agency's top immunization official announced the move Monday, citing Secretary ...